XADAGO Drug Patent Profile

Which patents cover Xadago, and what generic alternatives are available?

Xadago is a drug marketed by Mdd Us and is included in one NDA. There are three patents protecting this drug.

This drug has ninety-seven patent family members in thirty-one countries.

The generic ingredient in XADAGO is safinamide mesylate. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the safinamide mesylate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Xadago

A generic version of XADAGO was approved as safinamide mesylate by PRINSTON INC on April 25^th, 2024.

Summary for XADAGO

International Patents:	97
US Patents:	3
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for XADAGO

US Patents and Regulatory Information for XADAGO

XADAGO is protected by three US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Mdd Us	XADAGO	safinamide mesylate	TABLET;ORAL	207145-001	Mar 21, 2017	AB	RX	Yes	No	8,076,515		Y	Y
Mdd Us	XADAGO	safinamide mesylate	TABLET;ORAL	207145-002	Mar 21, 2017	AB	RX	Yes	Yes	8,278,485			Y
Mdd Us	XADAGO	safinamide mesylate	TABLET;ORAL	207145-001	Mar 21, 2017	AB	RX	Yes	No	8,278,485			Y
Mdd Us	XADAGO	safinamide mesylate	TABLET;ORAL	207145-001	Mar 21, 2017	AB	RX	Yes	No	8,283,380
Mdd Us	XADAGO	safinamide mesylate	TABLET;ORAL	207145-002	Mar 21, 2017	AB	RX	Yes	Yes	8,076,515		Y	Y
Mdd Us	XADAGO	safinamide mesylate	TABLET;ORAL	207145-002	Mar 21, 2017	AB	RX	Yes	Yes	8,283,380

International Patents for XADAGO

When does loss-of-exclusivity occur for XADAGO?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

China

Croatia

Cyprus

Denmark

Eurasian Patent Organization

European Patent Office

Hong Kong

Hungary

Israel

Japan

Lithuania

Mexico

New Zealand

Norway

Poland

Portugal

Serbia

Slovenia

South Korea

Spain

Taiwan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering XADAGO around the world.

Country	Patent Number	Title	Estimated Expiration
Serbia	53824	PROCES ZA DOBIJANJE 2-[4-(3-I 2-FLUORBENZILOKSI) BENZILAMINO] PROPANAMIDA (PROCESS FOR THE PRODUCTION OF 2-[4-(3- AND 2-FLUOROBENZYLOXY) BENZYLAMINO] PROPAN AMIDES)
Denmark	1613296
China	101472880
Croatia	P20150136
Denmark	2029524
Taiwan	200815322

Supplementary Protection Certificates for XADAGO

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1613296	300752	Netherlands		PRODUCT NAME: SAFINAMIDE; REGISTRATION NO/DATE: EU/1/14/984 20150224
1613296	132016000023012	Italy		PRODUCT NAME: SAFINAMIDE(XADAGO); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/14/984, 20150224
1613296	15C0054	France		PRODUCT NAME: SAFINAMIDE; REGISTRATION NO/DATE: EU/1/14/984 20150224
1613296	CA 2015 00042	Denmark		PRODUCT NAME: KOMBINATION AF SAFINAMID OG LEVOPODA/PDI; REG. NO/DATE: EU/1/14/984/001-010 20150224
1613296	CR 2015 00042	Denmark		PRODUCT NAME: KOMBINATION AF SAFINAMID, HERUNDER SAFINAMID METHANSULFONAT, OG LEVODOPA/PDI; REG. NO/DATE: EU/1/14/984/001-010 20150226
1613296	46/2015	Austria		PRODUCT NAME: SAFINAMIDE; REGISTRATION NO/DATE: EU/1/14/984 20150224

XADAGO (Safinamide) Investment Fundamentals and Patent Landscape

Last updated: February 19, 2026

Executive Summary

XADAGO (safinamide) is a selective, reversible monoamine oxidase B (MAO-B) inhibitor and sodium channel blocker approved for the adjunctive treatment of Parkinson's disease (PD) motor fluctuations. Its patent portfolio, primarily held by Newron Pharmaceuticals S.p.A., includes compound patents, formulation patents, and method of use patents, with key expirations in the United States and Europe anticipated in the coming years. Market exclusivity is further influenced by regulatory data protection periods. The competitive landscape for PD therapies is robust, featuring established treatments and emerging modalities. Investment viability hinges on XADAGO's market penetration, pricing strategies, and the ability of Newron to navigate patent cliffs and defend against generic competition.

What Is XADAGO's Mechanism of Action and Therapeutic Indication?

XADAGO, with the active pharmaceutical ingredient safinamide, operates through a dual mechanism. First, it selectively and reversibly inhibits MAO-B, an enzyme responsible for the breakdown of dopamine in the brain. This inhibition increases dopamine levels, a neurotransmitter crucial for motor control, which are deficient in Parkinson's disease. Second, safinamide modulates voltage-gated sodium channels, which contributes to a reduction in the release of excitatory amino acids, such as glutamate, from presynaptic neurons. This action is believed to offer neuroprotective effects.

The primary therapeutic indication for XADAGO is as an adjunctive therapy to levodopa and a dopamine agonist in patients with Parkinson's disease who experience "off" episodes, characterized by the return of motor symptoms between doses of their primary medication. This indication targets a significant unmet need in managing the fluctuating motor symptoms associated with advanced Parkinson's disease.

What Is the Current Patent Status of XADAGO?

The patent protection for XADAGO is distributed across several key areas, providing a multi-layered defense against generic competition.

Key Patent Families and Expiry Projections:

• US Patent 6,300,364 (Safinamide Mesilate Compound): This foundational patent covers the safinamide mesilate compound itself. It was granted on October 9, 2001. Under normal circumstances, this patent would expire on October 9, 2018. However, patent term extensions and adjustments can alter these dates. For XADAGO, the compound patent was extended in the U.S. to August 24, 2024, due to regulatory delays.
• EP Patent 0889733 (Safinamide Compound): This European Patent, covering the safinamide compound, had an initial expiry date of March 10, 2019. Similar to the US, extensions may have been applied for in individual European countries through Supplementary Protection Certificates (SPCs).
• Formulation Patents: Additional patents cover specific formulations of safinamide, potentially including extended-release or other advantageous delivery systems. These patents typically have later expiry dates than the original compound patents. For instance, patents covering specific polymorphic forms or pharmaceutical compositions are expected to expire in the mid-2020s and early 2030s.
• Method of Use Patents: Patents pertaining to specific methods of treating Parkinson's disease with safinamide, particularly for managing motor fluctuations, also contribute to patent protection. These patents are crucial for defending specific therapeutic applications. Expiry dates for these patents vary but are generally aligned with or slightly after the expiry of formulation patents.

Impact of Patent Expirations:

The approaching expiry of key compound and formulation patents in the U.S. and Europe signifies a critical juncture for XADAGO. Generic manufacturers will likely seek to launch bioequivalent versions of safinamide upon patent expiry, potentially leading to significant price erosion and market share reduction for the originator product. The precise timing of generic entry is influenced by the expiry of all relevant patents and any granted SPCs.

What is the Regulatory Exclusivity Status for XADAGO?

Regulatory exclusivity is a critical component of market protection, operating independently of patent protection.

• United States: Following FDA approval in March 2017, XADAGO benefits from a period of New Chemical Entity (NCE) exclusivity. For NCEs approved after the enactment of the Hatch-Waxman Act, this typically grants five years of market exclusivity against generic competition based on a different regulatory pathway. This period would have effectively ended in March 2022. However, patent extensions can be added to this period. The patent term extension for US patent 6,300,364 to August 24, 2024, effectively secures market exclusivity until that date.
• Europe: In the European Union, new active substances are granted eight years of data exclusivity from the date of the first marketing authorization. This is followed by a two-year period of market exclusivity, during which generic products cannot be marketed. This system, often referred to as the "8+2" regime, means that a generic application cannot be filed until the eight years of data exclusivity have passed, and the product cannot be marketed until the subsequent two years of market exclusivity have also passed. This effectively provides ten years of exclusivity from the initial marketing authorization date. For XADAGO, approved in the EU in April 2015, the data exclusivity period expired in April 2023, and market exclusivity would have expired in April 2025, unless extended by SPCs.

Impact of Regulatory Exclusivity:

Regulatory exclusivity provides a crucial buffer against generic entry, even if underlying patents have expired. The interplay between patent expiry and the end of regulatory exclusivity is paramount. In markets where patent protection is more robust or SPCs have been granted for longer periods, XADAGO's market exclusivity can extend beyond the initial patent expiry dates.

What Is the Competitive Landscape for Parkinson's Disease Therapies?

The Parkinson's disease therapeutic market is characterized by a diverse range of treatments, addressing different stages and symptoms of the disease.

Established Treatments:

• Levodopa: The gold standard treatment for Parkinson's, levodopa (often combined with carbidopa or benserazide), remains the most effective symptomatic therapy for motor symptoms. However, long-term use is associated with motor fluctuations and dyskinesias.
• Dopamine Agonists: Drugs like pramipexole, ropinirole, and rotigotine mimic the effects of dopamine and are used as monotherapy in early PD or as adjuncts to levodopa.
• MAO-B Inhibitors: Drugs such as selegiline and rasagiline (Azilect) also increase dopamine levels by inhibiting MAO-B. XADAGO competes directly within this class but offers a distinct mechanism and potentially a different efficacy/safety profile.
• COMT Inhibitors: Entacapone and opicapone are used to prolong the effect of levodopa by inhibiting the enzyme catechol-O-methyltransferase, which breaks down levodopa.
• Amantadine: Used to manage levodopa-induced dyskinesias.

Emerging Therapies and Modalities:

• New Drug Approvals: The pipeline for Parkinson's disease is active, with ongoing research into novel symptomatic treatments and disease-modifying therapies. Examples include new formulations of existing drugs, advanced delivery systems, and novel pharmacological targets.
• Gene Therapy and Cell-Based Therapies: While still largely experimental, gene therapy and stem cell-based approaches aim to restore dopaminergic function or provide neuroprotection, representing potential long-term disruptive forces.
• Non-Pharmacological Interventions: Deep brain stimulation (DBS) surgery is a well-established option for selected patients with advanced PD experiencing motor fluctuations refractory to medication.

XADAGO's Competitive Positioning:

XADAGO is positioned as an adjunctive therapy for patients experiencing motor fluctuations. Its dual mechanism of action, combining MAO-B inhibition with sodium channel modulation, offers a potential advantage over single-mechanism therapies. The competitive advantage of XADAGO will depend on its comparative efficacy, safety profile, tolerability, patient convenience, and pricing relative to other adjunctive options, including generic versions of older MAO-B inhibitors and other drug classes.

What Are the Market Size and Growth Prospects for Parkinson's Disease Therapeutics?

The Parkinson's disease therapeutics market is substantial and projected to grow, driven by several factors:

• Aging Global Population: Parkinson's disease incidence increases with age, and the aging demographic in many developed and developing countries will lead to a higher prevalence of PD.
• Improved Diagnosis and Awareness: Better diagnostic tools and increased public awareness contribute to earlier and more accurate diagnoses, expanding the patient population eligible for treatment.
• Unmet Needs in Disease Modification: While current therapies manage symptoms, there is a significant unmet need for treatments that can slow or halt disease progression. This fuels research and development, potentially leading to new market segments.
• Advancements in Treatment Options: The continuous introduction of new drugs, improved formulations, and advanced delivery systems expands therapeutic options and market value.

Market Size Estimates:

Global market size estimates for Parkinson's disease therapeutics vary by research firm, but generally fall within the range of $5 billion to $8 billion annually and are projected to grow at a compound annual growth rate (CAGR) of 5% to 7% over the next five to seven years. This growth is expected to be driven by increasing prevalence, rising healthcare expenditure, and the launch of novel therapies.

Factors Influencing XADAGO's Market Share:

• Efficacy in "Off" Time Reduction: XADAGO's ability to significantly reduce "off" time for patients is a key determinant of its market adoption.
• Safety and Tolerability Profile: A favorable side effect profile compared to other adjunctive therapies is crucial for long-term patient adherence and physician prescribing habits.
• Physician Prescribing Patterns: Adoption rates will depend on the willingness of neurologists and movement disorder specialists to incorporate XADAGO into their treatment algorithms.
• Payer Reimbursement and Pricing: Access and affordability are critical. Favorable reimbursement decisions and competitive pricing relative to existing and future therapies will impact market penetration.
• Generic Competition: The timing and impact of generic safinamide entry will be a primary factor in revenue erosion.

What Are the Key Risks and Opportunities for XADAGO?

Risks:

• Patent Expirations and Generic Competition: The most significant risk is the imminent expiry of key patents and the subsequent entry of generic safinamide. This will likely lead to substantial price decreases and a loss of market share.
• Competition from Existing and Emerging Therapies: The PD market is crowded. XADAGO faces competition from established treatments, including other MAO-B inhibitors (potentially at lower generic prices), and from novel therapies in development targeting different aspects of PD.
• Regulatory Hurdles and Reimbursement Challenges: Obtaining favorable reimbursement from payers globally can be challenging, impacting market access and sales volume.
• Clinical Trial Outcomes: Any adverse events or unexpected efficacy limitations discovered in post-market surveillance or ongoing trials could impact its long-term viability.
• Pipeline Competition: The continuous development of new Parkinson's treatments means that XADAGO could be superseded by more effective or convenient therapies.

Opportunities:

• Expansion into New Geographic Markets: Successful commercialization and regulatory approval in underserved regions can unlock new revenue streams.
• Development of New Formulations or Indications: Exploring extended-release formulations or investigating potential efficacy in other neurological conditions could extend the product lifecycle and create new market opportunities.
• Leveraging Dual Mechanism for Differentiated Value Proposition: The unique dual mechanism could be emphasized in marketing to highlight benefits beyond simple MAO-B inhibition, appealing to physicians seeking comprehensive symptomatic management.
• Strategic Partnerships and Licensing: Collaboration with larger pharmaceutical companies could provide the necessary resources for expanded marketing, research, and global reach.
• Disease-Modifying Potential Exploration: While currently indicated for symptomatic relief, any emerging evidence or research suggesting disease-modifying effects could dramatically alter its long-term value proposition and attract significant investment interest.

Key Takeaways

XADAGO (safinamide) holds a strategic position as an adjunctive therapy for Parkinson's disease motor fluctuations. Its market exclusivity is directly tied to the expiration of its patent portfolio, with key compound patents expiring in the United States in August 2024 and in Europe around March 2019 (with potential extensions via SPCs). Regulatory exclusivity periods have also been significant but are concluding or have concluded in core markets. The competitive landscape is dynamic, with ongoing innovation in PD treatment. Investment viability for XADAGO is contingent on its ability to maintain market share against impending generic competition, demonstrate superior clinical value, and navigate evolving reimbursement policies. Opportunities exist in geographic expansion and potential lifecycle management through new formulations or explored indications, but the primary challenge remains the patent cliff.

Frequently Asked Questions

1. When does the primary patent for safinamide expire in the United States? The U.S. compound patent 6,300,364 for safinamide mesilate, after patent term extension, is set to expire on August 24, 2024.

2. What is the typical length of regulatory data exclusivity for a new drug in Europe? In the European Union, new active substances generally receive eight years of data exclusivity from the date of their first marketing authorization, followed by two years of market exclusivity, totaling ten years of protection.

3. How does XADAGO's dual mechanism of action differentiate it from other MAO-B inhibitors? XADAGO's dual mechanism combines MAO-B inhibition with voltage-gated sodium channel modulation, which may offer additional neuroprotective benefits beyond the dopamine-increasing effect of selective MAO-B inhibition alone.

4. What are the main drivers of growth in the Parkinson's disease therapeutics market? Key drivers include the aging global population, increased prevalence of PD, improvements in diagnosis and awareness, and the ongoing demand for both symptomatic relief and disease-modifying therapies.

5. What is the most significant risk factor impacting XADAGO's future market performance? The most significant risk is the impending expiration of its core patent protections, which will open the market to generic competition, leading to potential price erosion and market share decline.

Citations

[1] Newron Pharmaceuticals S.p.A. (2023). Annual Report 2023. [2] European Medicines Agency. (n.d.). Hospitals and orphan drugs. Retrieved from https://www.ema.europa.eu/en/regulation-policy-law/incentives-and-rewards/hospitals-orphan-drugs [3] U.S. Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Retrieved from https://www.fda.gov/drugs/development-approval-process-drugs/orange-book-approved-drug-products-therapeutic-equivalence-evaluations [4] Various Market Research Reports on Parkinson's Disease Therapeutics Market. (Dates vary, ongoing analysis). [5] Publicly available patent databases (e.g., USPTO, Espacenet). (Data accessed periodically).